EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection – Epidemiology Forecast to 2022

Publisher Name :
Date: 15-Nov-2013
No. of pages: 54

Urinary tract infections (UTIs) are among the most common bacterial infections acquired in hospitals and in the community setting. A UTI can occur when daily living activities and medical interventions aid in the movement of bacteria into the urethra; however, bacterial colonization does not always lead to the development of UTI symptoms. Although UTIs can be caused by bacteria, viruses, or fungi, gram-negative bacteria are the pathogens most frequently associated with UTIs. Gram-negative bacteria have become increasingly resistant to individual antimicrobials, and of particular concern, is the emergence of multidrug-resistant activity in these organisms. Although there has been little change in the predominant causative pathogens in the past few decades, individual pathogen frequency and resistance patterns of gram-negative pathogens vary considerably between settings, countries, and continents.

According to GlobalData’s forecast, the number of incident cases of UTI will increase in the US during the forecast period. The largest number of cases will be classified as community-acquired and occur in women =80 years of age. The 5EU will see a slight increase in the number of healthcare-associated incident cases of UTI during the forecast period, with the highest number of cases occurring among women in Germany, and among those ages 70-79 years. Japan is forecast to see a large increase in the number of incident cases of UTI occurring during the forecast period in intensive care units, with the greatest number of cases occurring among women and those =80 years.

A major strength of this analysis is that GlobalData epidemiologists used country-specific sources for each market in the analysis and were able to obtain country-specific national surveillance data for the 5EU and Japan. The use of country-specific sources is especially important for antimicrobial resistance data as the rates of resistance have been found to vary considerably between countries. Additionally, because resistance rates have changed over time, GlobalData’s use of recent sources for resistance rates ensures that the estimates for the number of resistant cases of UTI reflect the most current situation in each market.

Scope

  • The Gram-Negative Bacterial Urinary Tract Infection (UTI) EpiCast Report provides an overview of the risk factors and global trends of UTI in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of UTI incident cases segmented by age (0-85 years and older), sex, causative pathogen (Escherichia coli, Klebsiella, Pseudomonas aeruginosa, Proteus, and Acinetobacter), multidrug resistance, and carbapenem resistance in these markets.
  • The UTI epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global UTI market.
  • Quantify patient populations in the global UTI market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex, age groups, pathogens, and antibiotic resistance patterns that present the best opportunities for UTI therapeutics in each of the markets covered.

EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection – Epidemiology Forecast to 2022

Table Of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8

3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.2.1 Women are more likely than men to experience UTI at all ages 11
3.2.2 The risk of developing UTI increases 3%-6% per day of catheterization 11
3.2.3 Older age is a major risk factor for UTI 12
3.2.4 Sexual intercourse can increase the relative odds of UTI in women by a factor as high as 60 13
3.2.5 Diabetic individuals have an increased incidence of UTI and increased associated complications 13
3.3 Forecast Methodology 14
3.3.1 Sources Used 15
3.3.2 Forecast Assumptions and Methods 19
3.4 Epidemiological Forecast for UTI (2012-2022) 24
3.4.1 US 24
3.4.2 5EU 29
3.4.3 Japan 36
3.5 Discussion 41
3.5.1 Conclusions on Epidemiological Trends 41
3.5.2 Limitations of the Analysis 42
3.5.3 Strengths of the Analysis 43

4 Appendix 44
4.1 Bibliography 44
4.2 About the Authors 49
4.2.1 Epidemiologists 49
4.2.2 Reviewers 49
4.2.3 Franka des Vignes, PhD, Global Director of Epidemiology and Health Policy 51
4.2.4 Bonnie Bain, PhD, Global Head of Healthcare 51
4.3 About GlobalData 52
4.4 About EpiCast 52
4.5 Disclaimer 53

List of Tables

Table 1: Risk Factors for Urinary Tract Infection 11
Table 2: Sources of Incidence Data Used in the Epidemiology Forecast 14
Table 3: US, Incident Cases of Gram-Negative UTI, N, by Site of Acquisition, Select Years, 2012-2022 25
Table 4: US, Incident Cases of Gram-Negative UTI, by Age and Site of Acquisition, N (Row %), 2012 26
Table 5: US, Incident Cases of Gram-Negative UTI, by Sex and Site of Acquisition, N (Row %), 2012 27
Table 6: US, Incident Cases of Gram-Negative UTI, by Pathogen and Site of Acquisition, N (Column %), 2012 28
Table 7: US, Incident Cases of Gram-Negative UTI, by Pathogen and Multidrug* and Carbapenem† Resistance, N, Percentage of Pathogen-Specific Cases, 2012 29
Table 8: 5EU, Incident Cases of UTI, N, Select Years, 2012-2022 30
Table 9: 5EU, Incident Cases of UTI, by Age, N (Row %), 2012 31
Table 10: 5EU, Incident Cases of UTI, by Sex, N (Row %), 2012 32
Table 11: 5EU, Incident Cases of UTI, by Pathogen, N (Percentage of Total Country-Specific Cases Caused by Pathogen), 2012 33
Table 12: 5EU, Incident Cases of UTI, by Pathogen and Multidrug and Carbapenem Resistance, N, and Percentage of Pathogen-Specific Cases, 2012 35
Table 13: Japan, Incident Cases of UTI, N, Select Years, 2012-2022 36
Table 14: Japan, Incident Cases of UTI, by Age, N (Row %), 2012 37
Table 15: Japan, Incident Cases of UTI, by Sex, N (Row %), 2012 38
Table 16: Japan, Incident Cases of UTI, by Pathogen, N (Percentage of Total Country-Specific Cases Caused by Pathogen), 2012 39
Table 17: Japan, Incident Cases of UTI, by Pathogen and Antibiotic, Number of Antibiotic-Resistant Cases (N) and Percentage of Antibiotic-Resistant Pathogen-Specific Cases (%), 2012 40

List of Figures

Figure 1: US, Incident Cases of Gram-Negative UTI, N, by Site of Acquisition, Select Years, 2012-2022 25
Figure 2: US, Incident Cases of Gram-Negative UTI, by Age and Site of Acquisition, N, 2012 26
Figure 3: US, Incident Cases of Gram-Negative UTI, by Sex, N, 2012 27
Figure 4: US, Incident Cases of Gram-Negative UTI, by Pathogen and Site of Acquisition, N, 2012 28
Figure 5: 5EU, Incident Cases of UTI, N, Select Years, 2012-2022 30
Figure 6: 5EU, Incident Cases of UTI, by Age, N, 2012 31
Figure 7: 5EU, Incident Cases of UTI, by Sex, N, 2012 32
Figure 8: 5EU, Incident Cases of UTI, by Pathogen, N, 2012 34
Figure 9: Japan, Incident Cases of UTI, N, Select Years, 2012-2022 36
Figure 10: Japan, Incident Cases of UTI, by Age, N, 2012 37
Figure 11: Japan, Incident Cases of UTI, by Sex, N, 2012 38
Figure 12: Japan, Incident Cases of UTI, by Pathogen, N, 2012 39

  • Global Stem Cell Therapy Industry Witnesses Steady Growth
    Stem cell research which is one of the most contemporary areas of biology has developed rapidly in the last couple of years. Increased funding in stem cell research by both government and private organizations is one of the main drivers in the stem cell therapy industry. Stem cells are used in various medical therapies such [...]
  • Global Lubricant Market Driven by Increased Demand in Automotive Industry
    With growth in the automobile industry, the demand for lubricants has also increased. The robust growth in manufacturing with increase in industrial production, particularly in countries such as China and India are also fueling the demand for lubricants. In 2013, the global market for lubricants had reached a value of 123.64 billion USD. By 2020, [...]
  • Global Cybersecurity Market Driven by Increase in Cyber Attacks
    In recent years, the global market for cybersecurity has grown steadily, with the rapid adoption of cloud-based services. As more and more corporate and government organizations are realizing the importance of protecting data and intellectual property, the market for cybersecurity is going to expand. In 2014, the global market for cybersecurity was valued at 95.60 [...]
  • Global Epilepsy Drug Market Continues to Grow Steadily
    The global epilepsy drug market has grown steadily in recent years with increased sales of anti-epileptic drugs which are targeted at reducing seizures. Epilepsy is a condition which affects the brain and is characterized with repeated seizures in the patient. Treatment for epilepsy usually involves the use of medicines known as anti-epileptic drugs which prevents [...]
  • Global Meat and Poultry Product Market to Witness Steady Growth
    As global demand for meat and poultry products continues to rise, the market for meat and poultry is also expected to grow steadily. The market for meat and poultry products is driven by rise in disposable income, growing awareness among consumers about the importance of adding protein to their diet, and change in eating habits. [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Aspergillosis Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 125
    GlobalData's clinical trial report, "Aspergillosis Global Clinical Trials Review, H2, 2014" provides data on the Aspergillosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Aspergillosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the ......
  • Cryptococcal Meningitis Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 79
    GlobalData's clinical trial report, "Cryptococcal Meningitis Global Clinical Trials Review, H2, 2014" provides data on the Cryptococcal Meningitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cryptococcal Meningitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, tr......
  • Cerebral (Fatal) Malaria Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 64
    GlobalData's clinical trial report, "Cerebral (Fatal) Malaria Global Clinical Trials Review, H2, 2014" provides data on the Cerebral (Fatal) Malaria clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cerebral (Fatal) Malaria. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase,......
  • African Trypanosomiasis Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 48
    GlobalData's clinical trial report, "African Trypanosomiasis Global Clinical Trials Review, H2, 2014" provides data on the African Trypanosomiasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on African Trypanosomiasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, tr......
  • Cryptosporidiosis Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 58
    GlobalData's clinical trial report, "Cryptosporidiosis Global Clinical Trials Review, H2, 2014" provides data on the Cryptosporidiosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cryptosporidiosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, promin......
  • Cytomegalovirus (CMV) Retinitis Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 70
    GlobalData's clinical trial report, "Cytomegalovirus (CMV) Retinitis Global Clinical Trials Review, H2, 2014" provides data on the Cytomegalovirus (CMV) Retinitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cytomegalovirus (CMV) Retinitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical t......
  • Dermatophytosis Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 86
    GlobalData's clinical trial report, "Dermatophytosis Global Clinical Trials Review, H2, 2014" provides data on the Dermatophytosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dermatophytosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence o......
  • Bacterial Sepsis Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 65
    GlobalData's clinical trial report, "Bacterial Sepsis Global Clinical Trials Review, H2, 2014" provides data on the Bacterial Sepsis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bacterial Sepsis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominenc......
  • Anthrax Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 79
    GlobalData's clinical trial report, "Anthrax Global Clinical Trials Review, H2, 2014" provides data on the Anthrax clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anthrax. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs